CN104997797B - A kind of pharmaceutical composition for treating infant eczema - Google Patents
A kind of pharmaceutical composition for treating infant eczema Download PDFInfo
- Publication number
- CN104997797B CN104997797B CN201510516051.4A CN201510516051A CN104997797B CN 104997797 B CN104997797 B CN 104997797B CN 201510516051 A CN201510516051 A CN 201510516051A CN 104997797 B CN104997797 B CN 104997797B
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- pharmaceutical composition
- eczema
- infant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 35
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 33
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 24
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims abstract description 16
- IUKLSMSEHKDIIP-BZMYINFQSA-N Verticine Chemical compound C([C@@H]1[C@@H](O)C[C@H]2[C@@H]3CC[C@@H]4[C@]5(C)O)[C@@H](O)CC[C@]1(C)[C@H]2C[C@H]3[C@@H]4CN1[C@H]5CC[C@H](C)C1 IUKLSMSEHKDIIP-BZMYINFQSA-N 0.000 claims abstract description 16
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 claims abstract description 15
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 claims abstract description 15
- IUKLSMSEHKDIIP-UHFFFAOYSA-N petine Natural products CC1(O)C2CCC3C4CC(O)C5CC(O)CCC5(C)C4CC3C2CN2C1CCC(C)C2 IUKLSMSEHKDIIP-UHFFFAOYSA-N 0.000 claims abstract description 15
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 claims abstract description 13
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 claims abstract description 13
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 claims abstract description 9
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 8
- 238000009833 condensation Methods 0.000 claims description 6
- 230000005494 condensation Effects 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 5
- 240000002853 Nelumbo nucifera Species 0.000 claims description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 20
- 206010014198 Eczema infantile Diseases 0.000 abstract description 11
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 6
- 206010067482 No adverse event Diseases 0.000 abstract description 3
- 230000001139 anti-pruritic effect Effects 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 208000003251 Pruritus Diseases 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 238000003756 stirring Methods 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 206010040882 skin lesion Diseases 0.000 description 5
- 231100000444 skin lesion Toxicity 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 229960002668 sodium chloride Drugs 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- SQHQDXGIJPHZRZ-AAWDLAKASA-N Jujuboside A Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@@H](O)CO[C@H]1O[C@@H]1C(C)(C)[C@H](CC[C@@]2(C)[C@@]34C[C@]5([C@H]([C@@](C[C@@H](O5)C=C)(C)O)[C@H]4CC[C@H]42)OC3)[C@]4(C)CC1 SQHQDXGIJPHZRZ-AAWDLAKASA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000238371 Sepiidae Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- KVKRFLVYJLIZFD-OPGZLHQPSA-N jujuboside A Natural products C[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC[C@@H]6[C@H]7[C@](C)(O)C[C@@H](O[C@@]78C[C@@]56CO8)C=C(C)C)C3(C)C)OC[C@H](O)[C@@H]2O[C@@H]9O[C@H](CO[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10O)[C@@H](O)[C@H](O)[C@H]9O[C@@H]%11OC[C@@H](O)[C@H](O)[C@H]%11O)[C@H](O)[C@H](O)[C@H]1O KVKRFLVYJLIZFD-OPGZLHQPSA-N 0.000 description 1
- QCLBRNPQMDEDIM-UHFFFAOYSA-N jujuboside C Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(O)COC1OC1C(C)(C)C(CCC2(C)C34CC5(C(C(CC(O5)C=C(C)C)(C)O)C4CCC42)OC3)C4(C)CC1 QCLBRNPQMDEDIM-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of pharmaceutical compositions for treating infant eczema, pharmaceutical composition of the present invention is using Saponin A, arctiin, Peimine, Nuciferine as raw material, it matches, routinely various dosage forms can be made by preparation process, the pharmaceutical composition for the treatment of infantile eczema provided by the invention, with clearing heat and detoxicating antipruritic effect, overcome that Western medicine side effect is big, infant should not largely be used for a long time, be discontinued the disadvantages of easy to recur, for infant eczema, it is easy to use, quick, clinical efficacy is definite, has no adverse reaction.
Description
Technical field
The present invention relates to a kind of Chinese medicine compositions, and in particular to a kind of Chinese medicine composition for treating infantile eczema.
Background technique
Infant Shi Shen is the common disease of paediatrics, and the cause of disease is complicated.Belong to Chinese medicine " infantile eczema ", " tire tinea ", " contamination is covered " or
" yellow water is covered ", " rotation ear is covered ", " skin diseases of the scrota " etc..Disease incidence is very high, there is statistics, infant eczema and anaphylaxis dermatosis
Account for about 30% or so of Pediatric Clinic case.Infant Pi Hongqi epidemic disease when eczema, endlessly, severe one can have exudation, routed disease, warts to itch,
The performance such as incrustation, this is sick or is limitation, or is systemic.Because etiology unknown, scope of medication are limited, diet and environment are difficult to
The factors such as control, compared with adult suffered from eczema, infantile eczema is easier to cause protracted course of disease, brings great pain to infant, more gives
Its family brings serious psychological burden and financial burden.At present to the treatment of eczema, doctor trained in Western medicine is adopted more using etiological treatment as principle
To antihistamine drug treatment for oral administration, such as diphenhydramine, chlorpheniramine, cyproheptadine, the cause of disease of eczema is complicated, although work compared with
Fastly, medication is more convenient, but side effect is larger, and is easy recurrent exerbation after being discontinued.Develop treatment infantile eczema it is safer, have
Effect, conveniently, the drug that uses of infant preferably it is extremely urgent.
Summary of the invention
The purpose of the present invention is overcoming the shortcomings of background technique, a kind of pharmaceutical composition for treating infant eczema is provided.
The present invention is achieved through the following technical solutions:
The composition and parts by weight of a kind of pharmaceutical composition bulk pharmaceutical chemicals for treating infant eczema of the invention are as follows: semen ziziphi spinosae soap
Glycosides A3-22 parts by weight, arctiin 4-24 parts by weight, Peimine 6-27 parts by weight, Nuciferine 8-30 parts by weight.
The composition and parts by weight of a kind of pharmaceutical composition bulk pharmaceutical chemicals for treating infant eczema of the invention are as follows: semen ziziphi spinosae soap
12 parts by weight of glycosides A, 15 parts by weight of arctiin, 12 parts by weight of Peimine, 18 parts by weight of Nuciferine.
The composition and parts by weight of a kind of pharmaceutical composition bulk pharmaceutical chemicals for treating infant eczema of the invention are as follows: semen ziziphi spinosae soap
Glycosides A8 parts by weight, 10 parts by weight of arctiin, 12 parts by weight of Peimine, 18 parts by weight of Nuciferine.
The composition and parts by weight of a kind of pharmaceutical composition bulk pharmaceutical chemicals for treating infant eczema of the invention are as follows: semen ziziphi spinosae soap
Glycosides A12 parts by weight, 8 parts by weight of arctiin, 27 parts by weight of Peimine, 8 parts by weight of Nuciferine.
A kind of pharmaceutical composition for treating infant eczema of the invention can be made soft of the conventional method of galenic pharmacy
Cream, gel, condensation.
A kind of pharmaceutical composition for treating infant eczema of the invention, it is characterised in that for treating infant eczema.
The invention has the advantages that modern Chinese herbal medicine preparation technique is used for the pharmaceutical composition, preparing clinic can be with
Ointment, gel, the condensation of receiving, it is good that patient takes compliance, quick using simple, has no adverse reaction, and it is easy to carry and
Storage, total effective rate reaches 88% or more according to clinical verification.
A kind of pharmaceutical composition for treating infant eczema provided by the invention has few, convenient to take, the clinical treatment of flavour of a drug
Imitate the features such as definite, the application of the drug can overcome Western medicine side effect is big, infant should not largely be used for a long time be discontinued it is easy to recur
The disadvantages of, it is eczema patients, new therapeutic agent is especially brought for infant patient.
Semen ziziphi spinosae, it is sweet in flavor, sour, it is mild-natured.Conscience can be nourished, is calmed the nerves, arrest sweating.
Great burdock achene, acrid flavour；It is bitter；It is cold in nature.Return lung；Stomach meridian, dispelling wind and heat from the body；Clearing heat and detoxicating promoting eruption；Promoting the dispersing function of the lung relieving sore-throat dissipates swollen.
Bulbus fritillariae cirrhosae, cold nature and sweet-bitter flavor, it is relieving cough and reducing sputum the benefits of it is stronger, enter cardiopulmonary warp, function moistening lung can be used for treating phlegm
Heat-syndrome cough asthma, the card of cough up phlegm yellow thick；Simultaneous sugariness again, therefore kind moistening lung to arrest cough, the card that treatment lung has scorching cough phlegm few and viscous, and yin
The asthenic symptoms such as empty cough caused by dryness overstrain cough；There are also the function of removing stasis and relieving uneasiness, treat vexed card and scrofula subcutaneous nodule etc. uncomfortable in chest caused by combination of phlegm and heat
Disease.In addition, bulbus fritillariae cirrhosae and cuttle bone, Radix Glycyrrhizae are powder, i.e. Medicinal powder of cuttlefish and firtillary bulb, treatment gastric ulcer is effective.
Traditional Chinese medicine thinks that lotus leaf, nature and flavor are bitter, mild-natured, returns liver, spleen, stomach, the heart channel of Hang-Shaoyin.There is clearing summer-heat and damp, sending up the lucid yang, cool
Blood hemostasis and other effects.Alkaloid in lotus leaf has effect for reducing blood fat, free radical resisting, inhibits hypercholesterolemia and artery sclerosis etc.
Medication, dietotherapy effect, but also there is antimitotic effect, there is stronger fungistatic effect.
Saponin A (jujuboside A): No. CAS: 55466-04-1, molecular formula: C58H94O26, molecular weight:
1207.35；
Arctiin (Arctiin), No. CAS: 20362-31-6, molecular formula: C27H34O11, molecular weight: 534.55226；
Peimine (Peimine), No. CAS: 23496-41-5, molecular formula: C27H45NO3, molecular weight: 431.65；
Nuciferine (nuciferine): No. CAS: 475-83-2, molecular formula: C19H21NO2, molecular weight: 295.376.
4 kinds of medicines structures of pharmaceutical composition of the present invention are as follows:
Specific embodiment
A kind of pharmaceutical composition for treating infant eczema of the invention is done below by specific embodiment and test example
Further instruction, but it is not limited to the present invention.
Embodiment 1: the pharmaceutical composition of infant eczema is treated
The composition and parts by weight for treating the raw material of the pharmaceutical composition of infant eczema are as follows:
12 parts by weight of A, 15 parts by weight of arctiin, 12 parts by weight of Peimine, 18 parts by weight of Nuciferine.
Embodiment 2: the pharmaceutical composition of infantile eczema is treated
The composition and parts by weight for treating the raw material of the pharmaceutical composition of infantile eczema are as follows:
8 parts by weight of Saponin A, 10 parts by weight of arctiin, 12 parts by weight of Peimine, 18 weight of Nuciferine
Part.
Embodiment 3: the pharmaceutical composition of infantile eczema is treated
The composition and parts by weight for treating the raw material of the pharmaceutical composition of infantile eczema are as follows:
12 parts by weight of Saponin A, 8 parts by weight of arctiin, 27 parts by weight of Peimine, 8 parts by weight of Nuciferine.
Embodiment 4: the pharmaceutical composition of infantile eczema is treated
The composition and parts by weight for treating the raw material of the pharmaceutical composition of infantile eczema are as follows:
10 parts by weight of Saponin A, 13 parts by weight of arctiin, 9 parts by weight of Peimine, 16 parts by weight of Nuciferine.
Embodiment 5: the preparation of gelling agent
The pharmaceutical composition 57g of Example 1 is spare, and carbomer is mixed with Tween-80 and 200mL distilled water,
Above-mentioned mixed liquor is added after being dissolved in 100mL distilled water in triethanolamine, stirs evenly spare, and vaseline is heated, part is melted
(about 1/2~3/5) stirs evenly, and when temperature is down to 50 DEG C, above-mentioned standby raw material is added and with adding with stirring, continues stirring until
Condensation is to get Shizhenling gel 1000g.
Embodiment 6: the preparation of condensation agent
1, by weight percentage by the pharmaceutical composition 47g (2..3%) of embodiment 2；Medicinal glycerine 4.50%；Sorbierite
0.10% is dissolved in purified water 15.00% and stirs evenly, and 15.00% sodium-chloride water solution is added dropwise to sodium chloride concentration to 0.8%-
1.1%；It is spare as hydrophilic solution.
2, by weight percentage by soybean oil 0.30%；Vitamin E 0.03% mixes, as oleophylic solution for standby.
3, by weight percentage by sodium alginate 5.00%；Gelatin 3.00%；It is added in purified water 20.00%, heats
To 50-60 degrees Celsius, stirring is opened, 15.00% sodium-chloride water solution is added dropwise to sodium chloride concentration to 0.8%-1.1%
And solution it is transparent it is thick after, as matrix, keep the temperature spare.
4, oleophylic solution is added drop-wise in matrix, is slowly added to hydrophilic solution, stirred, be cooled to room temperature, condition under vacuum
Under, it is filled into Clear glass bottles and jars, seals spiral cover.
Embodiment 7: the preparation of ointment
Take stearic acid 180g, lanolin 30g, atoleine 300ml, glycerol 60g, triethanolamine 10g, dodecyl sulphate
Matrix is made in sodium 20g, water 450ml, is uniformly mixed with the pharmaceutical composition 55g of embodiment 3, and the drug that can must treat eczema is soft
Cream about 1000g.
Embodiment 8: the preparation of ointment
Take stearic acid 180g, lanolin 30g, atoleine 300ml, glycerol 68g, triethanolamine 10g, dodecyl sulphate
Matrix is made in sodium 20g, water 450ml, is uniformly mixed with the pharmaceutical composition 47g of embodiment 2, and the drug that can must treat eczema is soft
Cream about 1000g.
Test example
Clinical data
1.1, general information
78 patients, age were 1 month ~ 2 one full year of life；The course of disease is mostly at 3 months to 1 year, average age 7 months；Wherein male 41
Example, female 37.
1.2 are included in case standard
Meet Western medicine diagnostic criteria (distinguishing chief editor " clinical dermatology " referring to Zhao):
(1) morbidity in 1-2 months after being born, is more common in fat or underfed infant；
(2) face, scalp, ear are predilection site, do not involve mouth week and nose portion generally；
(3) damage is multirow, there is rotten to the corn erythema, papule, blister, sepage and incrustation；
(4) itch, infant are had the fidgets；The course of disease is longer, and recurrent exerbation mostly mitigates after wean.
78 eczema infants meet eczema diagnostic criteria, betide any position of body surface, how symmetrical, occur red
Spot, indefinite border are mostly that intensive big papule, papulo-vesicle, phlysis and sepage or surface have canescence bran squama in erythema
Bits etc..Course of disease 4d to 2 years；Head And Face 35, it is dispersed in 28, four limbs 15 all over the body.
1.3, exclusion criteria
With congenital disorders patient；There is Chinese medicine allergies person；Other external preparations or whole body application are used in nearest 1 week
Corticosteroid and Loratadine；Skin lesion has rotten to the corn, exudation and suppuration person；Immunization campaign person during treatment；It does not meet and receives
Enter other cases of standard.
2, treatment method
The outer pharmaceutical composition gelling agent for taking embodiment 5,5 times a day.Two weeks for a course for the treatment of treats 1 course for the treatment of.Infant food
Its mother of breast milk person avoids pungent food and stimulates greasy food.
3, observation index
3.1 cardinal symptoms and sign erythema, papule, erosion, exudation, incrustation, itch.Using 4 grades of point systems, 0 point is
Nothing, 1 point be it is slight, 2 points be moderate, 3 points be severe.Objective scoring is carried out to pretherapy and post-treatment clinical symptoms and sign respectively.
3.2 curative effect determinate standards determine according to " the disease of tcm Standardization of diagnosis and curative effect " that State Administration of Traditional Chinese Medicine formulates:
Cure: itch disappears, skin lesion recession >=90%；Effective: pruritis is substantially reduced, skin lesion recession >=70%；It is effective:
Pruritis is mitigated, skin lesion recession >=30%；Invalid: pruritis is unchanged, skin lesion recession < 30%.The efficacy determination time
For 2 weeks after treatment.
4, result
4.1 treatments 78,37 (47.4%) of fully recovering is effective 32 (41.0%), effective 9 (11.6%), and invalid 0,
Total effective rate 88.4%.
4.2 integrate improvement before and after treatment is shown in Table 1
Note: P < 0.01 compared with before treatment * *.
5, adverse reaction
During treatment, 78 patients have no adverse reaction.
Typical case
Case 1: infant Mr. Wang, male, 10 months.
Symptom: infant Head And Face eczema, erythema, papule, itch very, rear affected part ulceration flowing water, formed yellow crusts, more after
It appears again, red tongue with yellowish fur.Condensation prepared by the embodiment of the present invention 6 is taken coated on affected part, is taken 1 course for the treatment of, is not occurred new
Fash, ulceration reduces, and incrustation obviously falls off, and itch mitigates, and continues to take 1 course for the treatment of, and recovery from illness, follow-up is without recurrence after half a year.
Case 2: infant Sun, 5 months.It is red and swollen on the face, it suppurates, itch is diagnosed as infant eczema, is implemented with the present invention
Ointment prepared by example 7 is coated on affected part, and after taking three times in 24 hours, redness subsides, the incrustation of suppuration position, after medication 5 days,
Recovery from illness, skin restore normal, and follow-up is without recurrence after half a year.
Claims (5)
1. a kind of pharmaceutical composition for treating infant eczema, it is characterised in that the composition of the bulk pharmaceutical chemicals of the pharmaceutical composition is made
And parts by weight are as follows: Saponin A 3-22 parts by weight, arctiin 4-24 parts by weight, Peimine 6-27 parts by weight, lotus leaf
Alkali 8-30 parts by weight.
2. a kind of pharmaceutical composition for treating infant eczema as described in claim 1, it is characterised in that the medicine group is made
Close the composition and parts by weight of the bulk pharmaceutical chemicals of object are as follows: 12 parts by weight of Saponin A, 15 parts by weight of arctiin, Peimine 12
Parts by weight, 18 parts by weight of Nuciferine.
3. a kind of pharmaceutical composition for treating infant eczema as described in claim 1, it is characterised in that the medicine group is made
Close the composition and parts by weight of the bulk pharmaceutical chemicals of object are as follows: 8 parts by weight of Saponin A, 10 parts by weight of arctiin, Peimine 12
Parts by weight, 18 parts by weight of Nuciferine.
4. a kind of pharmaceutical composition for treating infant eczema as described in claim 1, it is characterised in that the medicine group is made
Close the composition and parts by weight of the bulk pharmaceutical chemicals of object are as follows: 12 parts by weight of Saponin A, 8 parts by weight of arctiin, Peimine 27
Parts by weight, 8 parts by weight of Nuciferine.
5. a kind of pharmaceutical composition for treating infant eczema as described in claim 1, it is characterised in that using galenic pharmacy
Ointment, gel, condensation is made in conventional method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510516051.4A CN104997797B (en) | 2015-08-21 | 2015-08-21 | A kind of pharmaceutical composition for treating infant eczema |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510516051.4A CN104997797B (en) | 2015-08-21 | 2015-08-21 | A kind of pharmaceutical composition for treating infant eczema |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104997797A CN104997797A (en) | 2015-10-28 |
| CN104997797B true CN104997797B (en) | 2019-03-15 |
Family
ID=54370839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510516051.4A Active CN104997797B (en) | 2015-08-21 | 2015-08-21 | A kind of pharmaceutical composition for treating infant eczema |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104997797B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100840A (en) * | 2009-12-17 | 2011-06-22 | 天津市中宝制药有限公司 | Traditional Chinese medicine composition for treating eczema |
| CN103877485A (en) * | 2014-04-08 | 2014-06-25 | 张竹梅 | Traditional Chinese medicine composition for treating eczema |
| CN104524345A (en) * | 2015-01-26 | 2015-04-22 | 何丹 | Traditional Chinese medicine for treating infantile eczema |
-
2015
- 2015-08-21 CN CN201510516051.4A patent/CN104997797B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100840A (en) * | 2009-12-17 | 2011-06-22 | 天津市中宝制药有限公司 | Traditional Chinese medicine composition for treating eczema |
| CN103877485A (en) * | 2014-04-08 | 2014-06-25 | 张竹梅 | Traditional Chinese medicine composition for treating eczema |
| CN104524345A (en) * | 2015-01-26 | 2015-04-22 | 何丹 | Traditional Chinese medicine for treating infantile eczema |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104997797A (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106924378B (en) | Chinese herbal medicine lipstick for preventing and/or treating chronic cheilitis | |
| CN113209238A (en) | Lotion for treating hand-foot syndrome caused by targeted medicament and preparation method thereof | |
| CN106361993B (en) | Pharmaceutical composition for preventing and treating gastric mucosal injury and preparation method thereof | |
| CN105106440B (en) | A traditional Chinese medicine composition for treating headache and dizziness after spinal anesthesia | |
| CN103830657A (en) | Medicine for treating chronic cholecystitis | |
| CN104997797B (en) | A kind of pharmaceutical composition for treating infant eczema | |
| CN114869949B (en) | A pharmaceutical composition for treating puerperal diseases, and its preparation method | |
| CN107126490A (en) | A kind of Chinese medicine composition for preventing and treating gastrointestinal dysfunction and preparation method thereof | |
| CN116236550A (en) | Light traditional Chinese medicine formula preparation for treating novel coronavirus infection and preparation method thereof | |
| CN115814046A (en) | Traditional Chinese medicine composition for treating mastitis and application thereof | |
| CN107496525A (en) | A kind of Chinese medicine composition for treating cancer pain disease and its application | |
| CN107048104A (en) | A kind of astaxanthin beverage for auxiliary treatment diabetes | |
| CN105726634A (en) | Traditional Chinese medicine preparation for treating rhinitis | |
| CN110652537A (en) | External application preparation for treating facial stains | |
| CN110101800A (en) | It is a kind of to treat malignant pleural effusion Chinese medicine composition and its application | |
| CN111228367A (en) | Traditional Chinese medicine external lotion for treating infantile anaphylactoid purpura and preparation method thereof | |
| CN104147274B (en) | Treat the psoriasic Chinese medicine composition of stagnated heat of liver channel type | |
| CN108210725B (en) | A kind of blood-raising medicinal composition and preparation method thereof | |
| CN108014237A (en) | A kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application | |
| CN108159232B (en) | Traditional Chinese medicine preparation for reducing postoperative recurrence and metastasis of colorectal cancer and preparation method and application thereof | |
| CN106581468A (en) | Preparation method of traditional Chinese medicine capable of treating gastric ulcer | |
| CN105535840B (en) | A kind of oral drugs for the treatment of of advanced leucoderma | |
| CN106924679A (en) | A kind of medicine for treating gastric ulcer | |
| CN118286353A (en) | Traditional Chinese medicine composition for treating oral mucositis of patient caused by radiotherapy and chemotherapy | |
| CN118526562A (en) | Traditional Chinese medicine compound composition for protecting sperm DNA integrity and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201231 Address after: 236000 2nd floor, building 5, Zhongke International Precision Industrial Park, Taihe Economic Development Zone, Fuyang City, Anhui Province Patentee after: ANHUI BAOJIN MEDICINE Co.,Ltd. Address before: 261500 Gaomi maternal and child health hospital, 3188 Fenghuang street, Gaomi City, Weifang City, Shandong Province Patentee before: Wang Fang |
|
| TR01 | Transfer of patent right |